Introduction
============

Nasopharyngeal carcinoma (NPC) is a common malignant neoplasm in Asia, and the most effective treatment is radiotherapy, over 80% of NPC patients now have long term survival, and secondary malignancy is one of the major late complications \[[@b1-crt-2019-202],[@b2-crt-2019-202]\]. Squamous cell carcinoma (SCC) is one of the most common secondary malignancies \[[@b3-crt-2019-202],[@b4-crt-2019-202]\]. Only a few researchers have analyzed the oncologic outcome of secondary SCC in head and neck \[[@b5-crt-2019-202]-[@b9-crt-2019-202]\] and presented the prognosis was quite poor. Oral SCC could also occur without previous radiotherapy \[[@b10-crt-2019-202]-[@b12-crt-2019-202]\], whether there is survival difference between the two groups remains unclear, therefore, the main goal of the current study was to analyze the prognosis of secondary oral SCC with a comparison with sporadic oral SCC by a matched-pair design.

Materials and Methods
=====================

1. Patients and samples
-----------------------

Medical records of consecutive patients with surgically treated primary oral SCC were reviewed between January 1985 to January 2019, enrolled patients must meet the following criteria: there was prior history of radiotherapy for NPC, and the latency between the diagnosis of oral SCC and the end of radiotherapy was not less than 3 years \[[@b13-crt-2019-202],[@b14-crt-2019-202]\]. Information regarding age, sex, operation record, treatment, and follow-up was collected and analyzed. All the pathologic sections were re-evaluated and patients were re-staged by the 7th edition American Joint Committee on Cancer classification.

To compare the survival between NPC survivors and sporadic oral SCC patients, patients with sporadic oral SCC were also reviewed during the same study period, each NPC survivor was matched with two sporadic oral SCC patients, the matching process was performed by age (±5 years), sex, primary tumor site, perineural invasion, lymphovascular invasion, smoker, disease stage (stage I/II vs. stage III/IV), neck node status (positive vs. negative), and tumor stage (T1/T2 vs. T3/T4) \[[@b11-crt-2019-202]\]. Perineural invasion was considered to be present if tumor cells were identified within the perineural space and/or nerve bundle, lymphovascular infiltration was positive if tumor was noted within the lymphovascular channels \[[@b15-crt-2019-202]\]. Drinkers were defined as those who consumed at least one alcoholic drink per day for at least 1 year \[[@b11-crt-2019-202],[@b16-crt-2019-202]\], smokers were defined as those smoked on a daily basis or had quit smoking for less than 5 years \[[@b11-crt-2019-202]\].

2. Statistical analysis
-----------------------

The chi-square test was used to compare the demographic and clinical pathologic variables between the two groups. In survival analysis, variables of age, sex, perineural invasion, lymphovascular invasion, node stage, tumor stage, disease stage, and disease grade were included. The main oncologic outcome of interests were overall survival (OS) and diseasespecific survival (DSS). The OS was calculated from the time of the oral SCC diagnosis until death or the last follow-up. The DSS was defined as the time from the oral SCC diagnosis to cancer-caused death or the last follow-up \[[@b5-crt-2019-202],[@b6-crt-2019-202]\]. The Kaplan-Meier method was used to evaluate the OS and DSS rates. Factors which were significant in univariate analysis (logrank method) were then analyzed by Cox model analysis to identify the independent risk factors for the OS and DSS rates. A p \< 0.05 was considered significant, and all statistical analyses were performed with SPSS ver. 20.0 (IBM Corp., Armonk, NY).

3. Ethical statement
--------------------

The Zhengzhou University institutional research committee approved our study, and all participants provided written informed consent for medical research prior to initial treatment, and all experiments were performed in accordance with relevant guidelines and regulations.

Results
=======

A total of 83 NPC survivors (67 male and 16 female) from 1430 patients with oral SCC were enrolled for analysis, the mean age was 63.4 years (range, 37 to 72 years). The mean latency from initial NPC to diagnosis of current oral SCC was 10.5 years (range, 4 to 32 years). Among the 83 patients, 72 cases had received conventional radiotherapy for NPC, and 11 cases had received 3D conformal radiation therapy or intensity-modulated radiation therapy for NPC. The mean radiation dose for NPC was 64.7 Gy (range, 51.4 to 79.2 Gy).

Negative margin was achieved in all patients. Neck dissection was performed in all the 83 cases, including five cases of radical neck dissection, seven cases of modified radical neck dissection, and 77 cases of selective dissection. Pathologic neck metastasis was noted in 28 patients.

In the 83 NPC survivors, 54 patients were diagnosed with tongue SCC, six cases with SCC of the mouth floor, 13 cases of buccal SCC, and 10 cases of lower gingiva SCC. During the same study period, 1,158 sporadic SCC patients of the tongue, mouth floor, buccal, and lower gingiva were also included for comparing. Comparison of demographic and clinical pathologic variables between NPC survivors and sporadic oral SCC patients was presented in [Table 1](#t1-crt-2019-202){ref-type="table"}. NPC survivors were less likely to be smokers (p=0.004), perineural invasion and lymphovascular invasion were more common in NPC survivors than sporadic oral SCC patients (both p \< 0.001). No significant difference regarding age, sex, and other adverse pathologic characteristics as well as adjuvant treatment was noted between the two groups (all p \> 0.05).

In NPC survivors, the mean follow-up time was 60.7 months (range, 9 to 221 months), 50 patients died, and in these 50 patients, 36 cases died of the disease, the 5-year OS and DSS rates were 47% and 54%, respectively. After being matched ([Table 2](#t2-crt-2019-202){ref-type="table"}), in sporadic oral SCC group, the mean follow-up time was 70.1 months (range, 8 to 264 months), 66 patients died, and 50 cases died of the disease, the 5-year OS and DSS rates were 62% and 67%, respectively. The two groups had significantly different 5-year OS and DSS rates (both p \< 0.05) ([Figs. 1](#f1-crt-2019-202){ref-type="fig"} and [2](#f2-crt-2019-202){ref-type="fig"}).

In further analysis of predictors for the OS in NPC survivors, the factors of smoker, tumor site, disease stage, node stage, and differentiation were significantly associated with the OS in univariate analysis, further Cox model confirmed the independence of smoker, disease stage, and differentiation in predicting the OS ([Table 3](#t3-crt-2019-202){ref-type="table"}).

In further analysis of predictors for the DSS in NPC survivors, the factors of smoker, tumor stage, disease stage, perineural invasion, and treatment were significantly associated with the DSS in univariate analysis, further Cox model confirmed the independence of disease stage, perineural invasion, and treatment in predicting the DSS ([Table 4](#t4-crt-2019-202){ref-type="table"}).

Discussion
==========

Secondary oral SCC was relatively uncommon after radiotherapy for NPC with an incidence of less than 5% \[[@b5-crt-2019-202]-[@b8-crt-2019-202],[@b17-crt-2019-202]-[@b19-crt-2019-202]\]. Very few researchers had analyzed the prognosis of oral SCC in NPC survivors. Sun et al. \[[@b7-crt-2019-202]\] retrospectively analyzed 68 patients who had then developed tongue SCC after radiotherapy for NPC, the authors depicted eight of these patients had clinical lymph node metastasis, and 45 presented with stage I-II disease at the time of the diagnosis. Surgery or radiotherapy alone was an effective treatment for patients with stage I-II tongue SCC, but patients with stage III-IV disease had a poor prognosis. Song et al. \[[@b8-crt-2019-202]\] reported of the 62 included patients, 42 patients died, the 3- and 5-year OS rates were 41% and 30%, respectively. Both two studies failed to compare the prognosis difference between NPC survivors and sporadic oral SCC patients. Zhang et al. \[[@b6-crt-2019-202]\] enrolled 73 patients with tongue SCC following radiotherapy, and the authors described that NPC survivors were less likely to have lymph node metastasis, but more likely to have a more advanced T classification, compared to sporadic tongue SCC patients, NPC survivors had worse OS but similar disease-free survival. Similar finding was reported regarding gingiva SCC by the same research team \[[@b5-crt-2019-202]\]. But in the above-mentioned two studies, the two groups had different tumor stage, node stage, and disease stage, all the variation could affect the comprehension of their outcome. The current study was firstly performed by a matched-pair design to shield the interfere of as many as confounding factors \[[@b20-crt-2019-202]\], it was noted NPC survivors had worse OS and DSS compared to sporadic oral SCC. At least the following three aspects called for consideration: in the one hand, there was negative prognostic effect of the previous radiotherapy on the survival of patients with oral SCC by prior researchers \[[@b21-crt-2019-202]\]. On the other hand, the difference in the immune status and the accumulation of genetic damage due to a history of radiation could help explain this situation, in addition, the excess mortality due to NPC and severe late complications was also partially responsible \[[@b22-crt-2019-202],[@b23-crt-2019-202]\].

Smoking was a common risk factor for the development of oral SCC, but less smokers were noted in NPC survivors in the current study. The finding might support the viewpoint that oral SCC in the NPC survivors and sporadic oral SCC might have different carcinogenesis \[[@b24-crt-2019-202]\], the sporadic oral SCC patients were more likely to be accompanied by mucosal field-cancerization, such as smoking. But in NPC survivors, the most possible explanation was the involvement of the bystander effect in cancer induction, it might induce the DNA impairment \[[@b25-crt-2019-202]\].

Perineural invasion and lymphovascular invasion were widely investigative predictors for poor prognosis in oral SCC patients, strongly correlating with tumor site, tumor stage, and disease stage \[[@b26-crt-2019-202],[@b27-crt-2019-202]\]. It was noted perineural invasion and lymphovascular invasion were more frequent in NPC survivors, the finding was a little out of our expectation. In a previous paper published by Zhang et al. \[[@b6-crt-2019-202]\], compared to sporadic tongue SCC patients, NPC survivors tended to have a low risk of the worst pattern of invasion and low tumor budding, both the two markers were independent predictors for poor prognosis. No other similar literature was available for comparing, the current study was the first to find there is a significantly higher prevalence of perineural invasion and lymphovascular invasion in NPC survivors. Tissue damage and increased vascular osmotic fragility caused by the previous radiotherapy might be partially responsible for the finding. Another possible explanation was that there might be different gene mutation between the two groups, some authors had described a mutation in BRCA1, BRCA2, and p53 was noted in patients' radiationassociated breast carcinoma \[[@b28-crt-2019-202]\], there might be a similar phenomenon in oral SCC, but it required more studies.

Prognostic factors for the survival in NPC survivors were rarely analyzed \[[@b7-crt-2019-202],[@b8-crt-2019-202]\]. Song et al. \[[@b8-crt-2019-202]\] concluded the key prognostic factors influencing the survival were age when NPC was diagnosed, TNM stage, and surgery treatment modality. Multivariate analysis revealed that the clinical TNM stage was an independent risk factor for patient survival. Sun et al. \[[@b7-crt-2019-202]\] described the risk factors influencing the survival of these patients independently were recurrence of their NPC, use of alcohol, the clinical TNM stage, and the latency period in multivariate analysis. Similar finding was also noted in current research, moreover, other well known prognostic predictors in sporadic oral SCC were also confirmed in NPC survivors.

The main treatment for oral SCC was the combined therapy dominated by surgery. For NPC survivors, it was difficult to choose the right time and dose to conduct radiotherapy, as re-irradiation was tolerable and feasible in properly selected patients who have a radiation history, it might improve the survival \[[@b5-crt-2019-202]\]. Postoperative re-irradiation should be advised in the case that patients required more disease control at the expense of higher toxicity \[[@b5-crt-2019-202],[@b9-crt-2019-202]\].

All the literature regarding secondary head neck SCC including this study was retrospective or was described by demographic results; we hope the current research could provide assistance in learning this relatively uncommon cancer type and looking for better ways to analyze and control its progression.

Limitation of this study must be acknowledged: firstly, there was inherent bias in a retrospective study. Second, the sample size was relatively small, possibly reducing the statistical power, therefore, larger sample-size studies were needed to clarify the question.

In summary, NPC survivors had worse OS and DSS than sporadic oral SCC patients, NPC survivors were less likely to be smokers, but had a higher opportunity of perineural invasion and lymphovascular invasion. Disease stage was the most important predictor for the survival in NPC survivors.
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###### 

Demographic and clinical pathologic information between NPC survivors and sporadic oral SCC patients

                                NPC survivor (n=83)   Sporadic oral SCC (n=1,158)   p-value
  ----------------------------- --------------------- ----------------------------- ----------
  **Age (yr)**                                                                      
   ≥ 60                         46                    632                           0.881
   \< 60                        37                    526                           
  **Sex**                                                                           
   Male                         67                    891                           0.428
   Female                       16                    267                           
  **Drinker**                                                                       
   Yes                          8                     200                           0.072
   No                           75                    958                           
  **Smoker**                                                                        
   Yes                          11                    323                           0.004
   No                           72                    835                           
  **Tumor site**                                                                    
   Tongue                       54                    486                           0.004
   Mouth floor                  6                     312                           
   Buccal                       13                    203                           
   Lower gingiva                10                    157                           
  **Tumor stage**                                                                   
   T1+T2                        59                    736                           0.167
   T3+T4                        24                    422                           
  **Disease stage**                                                                 
   I+Ⅱ                          51                    633                           0.230
   Ⅲ+Ⅳ                          32                    525                           
  **Node stage**                                                                    
   N0                           55                    789                           0.724
   N+                           28                    369                           
  **Differentiation**                                                               
   Well                         47                    554                           0.133
   Moderate                     23                    377                           
   Poor                         13                    167                           
   Unknown                      0                     60                            
  **Perineural invasion**                                                           
   Positive                     23                    130                           \< 0.001
   Negative                     60                    949                           
   Unknown                      0                     79                            
  **Lymphovascular invasion**                                                       
   Positive                     16                    153                           \< 0.001
   Negative                     67                    955                           
   Unknown                      0                     50                            
  **Treatment**                                                                     
   S                            15                    145                           0.235
   S+R                          30                    369                           
   S+R+C                        38                    612                           

NPC, nasopharyngeal carcinoma; SCC, squamous cell carcinoma; S, surgery; R, radiotherapy; C, chemotherapy.

###### 

Information comparison between NPC survivors and matched group

                                NPC survivor (n=83)   Matched group (n=166)   p-value
  ----------------------------- --------------------- ----------------------- ---------
  **Age (yr)**                                                                
   ≥ 60                         46                    88                      0.719
   \< 60                        37                    78                      
  **Sex**                                                                     
   Male                         67                    134                     \> 0.99
   Female                       16                    32                      
  **Drinker**                                                                 
   Yes                          8                     25                      0.234
   No                           75                    141                     
  **Smoker**                                                                  
   Yes                          11                    22                      \> 0.99
   No                           72                    144                     
  **Tumor site**                                                              
   Tongue                       54                    108                     \> 0.99
   Mouth floor                  6                     12                      
   Buccal                       13                    26                      
   Lower gingiva                10                    20                      
  **Tumor stage**                                                             
   T1+T2                        59                    118                     \> 0.99
   T3+T4                        24                    48                      
  **Disease stage**                                                           
   Ⅰ+Ⅱ                          51                    102                     \> 0.99
   Ⅲ+Ⅳ                          32                    64                      
  **Node stage**                                                              
   N0                           55                    110                     \> 0.99
   N+                           28                    56                      
  **Differentiation**                                                         
   Well                         47                    92                      0.891
   Moderate                     23                    44                      
   Poor                         13                    30                      
  **Perineural invasion**                                                     
   Positive                     23                    46                      \> 0.99
   Negative                     60                    120                     
  **Lymphovascular invasion**                                                 
   Positive                     16                    32                      \> 0.99
   Negative                     67                    134                     
  **Treatment**                                                               
   S                            15                    22                      0.601
   S+R                          30                    64                      
   S+R+C                        38                    80                      

NPC, nasopharyngeal carcinoma; S, surgery; R, radiotherapy; C, chemotherapy.

###### 

Prognostic factors for the overall survival in NPC survivors

  Variable                                   Univariate Log-rank test   Cox model              
  ------------------------------------------ -------------------------- ---------------------- ----------
  Age (≥ 60 yr vs. \< 60 yr)                 0.358                      \-                     \-
  Sex (male vs. female)                      0.288                      \-                     \-
  Drinker (yes vs. no)                       0.112                      \-                     \-
  Smoker (yes vs. no)                        0.025                      1.963 (1.275-4.002)    0.031
  Tumor site (tongue vs. others)             0.034                      2.111 (0.687-8.244)    0.657
  Tumor stage (T1+T2 vs. T3+T4)              0.096                      \-                     \-
  Node stage (N0 vs. N+)                     0.044                      3.013 (0.846-6.897)    0.273
  Disease stage (Ⅰ+Ⅱ vs. Ⅲ+Ⅳ)                0.008                      3.482 (1.852-10.336)   \< 0.001
  Differentiation (well vs. moderate+poor)   0.017                      2.541 (1.344-6.579)    0.005
  Perineural invasion (yes vs. no)           0.324                      \-                     \-
  Lymphovascular invasion (yes vs. no)       0.119                      \-                     \-
  Treatment (surgery alone vs. others)       0.613                      \-                     \-

NPC, nasopharyngeal carcinoma; HR, hazard ratio; CI, confidence interval.

###### 

Prognostic factors for the disease-specific survival in nasopharyngeal carcinoma survivors

  Variable                                   Univariate Log-rank test   Cox model              
  ------------------------------------------ -------------------------- ---------------------- ----------
  Age (≥ 60 yr vs. \< 60 yr)                 0.147                      \-                     \-
  Sex (male vs. female)                      0.638                      \-                     \-
  Drinker (yes vs. no)                       0.241                      \-                     \-
  Smoker (yes vs. no)                        0.013                      1.951 (0.847-3.003)    0.287
  Tumor site (tongue vs. others)             0.378                      \-                     \-
  Tumor stage (T1+T2 vs. T3+T4)              0.016                      2.631 (0.411-6.387)    0.612
  Node stage (N0 vs. N+)                     0.188                      \-                     \-
  Disease stage (Ⅰ+Ⅱ vs. Ⅲ+Ⅳ)                0.007                      4.021 (1.637-13.554)   \< 0.001
  Differentiation (well vs. moderate+poor)   0.087                      \-                     \-
  Perineural invasion (yes vs. no)           0.016                      2.002 (1.174-3.982)    0.011
  Lymphovascular invasion (yes vs. no)       0.325                      \-                     \-
  Treatment (surgery alone vs. others)       0.023                      1.988 (1.164-3.863)    0.013

HR, hazard ratio; CI, confidence interval.
